Vitamin D and COVID-19
| Condition | Age/years old | Study | Results | Reference |
|---|---|---|---|---|
| COVID-19 and vitamin D levels | 65 ± 13 70 ± 14 | Levels of vitamin D 12 ng/mL or 8 ng/mL | Survivors presented higher levels of vitamin D than non-survivors | [87] |
| COVID-19 and vitamin D levels | Median 63 | Levels of vitamin D 17 ng/mL to 33 ng/mL | No correlation between prehospitalization vitamin D and clinical outcomes | [91] |
| COVID-19, vitamin D supplement | 66 ± 11 65 ± 11 | 200,000 IU vitamin D intramuscularly 1 mcg/day vitamin D orally | Reduced incidence of mechanical ventilation, ICU, death, sepsis and atrial fibrillation in higher dose intramuscularly | [92] |
| COVID-19, vitamin D supplement | 59 ± 10 | High single oral dose 500,000 IU x placebo | No prevention in the respiratory worsening and no significant effects on the length of hospital stay | [93] |
| COVID-19, vitamin D supplement | 56 ± 14 | High single oral dose 200,000 IU x placebo | Similar length of hospital stays, in-hospital mortality, ICU, mechanical ventilation | [94] |
| COVID-19, vitamin D, and vaccination | 53–69 | 800 IU/day or 3,200 IU/day x placebo | No difference on breakthrough SARS-CoV-2 infection, post-vaccination titers of anti-S or neutralizing antibodies | [95] |
| COVID-19, vitamin D, and vaccination | 40 ± 11 | Vitamin D levels higher than 50 nmol/L | Higher levels of anti-S post-vaccine | [96] |
